GLP-1 RAs help slow CKD and lower heart disease risk for people with type 2 diabetes and/or obesity, but its important to weigh risks and benefits. Table of Contents. About GLP-1 Receptor Agonists (GLP-1 RAs).
Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are one option. In this article, Dr. Maria Prelipcean explains how GLP-1 agonists work, their benefits and risks, and some common side effects.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established as effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as monotherapy or in combination with oral glucose-lowering drugs insulin.
The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide...
The combined therapy of GLP-1 receptor agonists (GLP-1RA) and basal insulin has emerged as an effective strategy for the management of type 2 diabetes mellitus (T2DM), offering benefits in glycated hemoglobin (HbA1c) reduction, weight control and a lower risk of hypoglycemia.
The realisation of this potential has developed rapidly, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now a standard feature in management guidelines for type 2 diabetes.
Here David Morris discusses their original use and efficacy for patients with type 2 diabetes. This image depicts a close-up view of the molecular structure of Semaglutide, a synthetic glucagon-like peptide 1 (GLP-1) receptor agonist.
The first compared GLP-1 receptor agonist users with nonusers among patients with obesity but without type 2 diabetes.The signal became even more dramatic in the comparison between GLP-1 receptor agonists and insulin or metformin among patients with type 2 diabetes.
Research continues to demonstrate the benefits of glucagon-like peptide-1 receptor (GLP-1R) agonists or co-agonists for type 2 diabetes (T2D).
